Bjarke Brandt H.
- Country
- Denmark
- Department
- Department of Rheumatology
Research Overview
- Long-Term Extension Study of RO7790121 (Afimkibart) for Safety and Efficacy in Adults with Moderate-to-Severe Rheumatoid Arthritis
- Efficacy and Safety of Subcutaneous Guselkumab in Bio-naive Patients with Active Psoriatic Arthritis Axial Disease: A Phase 4 Randomized, Double-blind, Placebo-controlled Study
- A Phase 3 Randomized Double-Blind Trial of Risankizumab Versus Placebo in Patients with Active Psoriatic Arthritis and Prior Biologic Therapy Inadequacy
Data & Insights
Has run more than one trial at 69 of 196 partner sites.
Specializations
Inflammatory Arthritis
This investigator specializes in treating psoriatic arthritis (PsA), with particular emphasis on both axial manifestations and peripheral joint involvement.
- Axial psoriatic arthritis management
- Novel therapeutic approaches
- Biologic therapy assessment
Focus includes evaluation of treatment responses in patients with varying disease presentations and therapeutic histories.
Immune-Mediated Disorders
Expertise in immunological therapeutic interventions for autoimmune conditions, particularly investigating advanced treatment options for resistant cases.
- Biologic therapy optimization
- Treatment-resistant conditions
- Novel therapeutic agents
Specialized interest in treating both biologic-naïve and biologic-experienced patient populations.
Clinical Assessment
Active involvement in evaluating therapeutic efficacy and monitoring disease progression in inflammatory arthritis.
- Symptom reduction assessment
- Treatment response evaluation
- Long-term outcome monitoring
Focuses on comprehensive assessment of treatment effects on various disease manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.